Cerebral Atherosclerosis Research With Positron Emission Tomography (NCT07041372) | Clinical Trial Compass
By InvitationNot Applicable
Cerebral Atherosclerosis Research With Positron Emission Tomography
South Korea310 participantsStarted 2021-06-22
Plain-language summary
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:
* Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
* Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.
Participants will:
* Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
* Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
* Maintain regular clinic visits for up to 24 months following the index stroke
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* acute ischemic stroke patients who admitted within seven days after symptom onset
Exclusion Criteria:
* Patients with unstable vital signs or neurological symptoms
* Patients with estimated glomerular filtration rate less than 30ml/min
* Patients with uncontrolled diabetes requiring persistent insulin injection
* During pregnancy or while breastfeeding
* Patients with impaired consent capacity
* Patients with diagnosed/treatment for dementia
* Patients undergoing treatment for malignant tumors or serious autoimmune diseases
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.